Krebs Biochemicals and Industries Limited
Krebs Biochemicals & Industries Limited engages in the manufacture and sale of active pharmaceutical ingredients in India. The company develops biotech processes for application in medicine, agriculture, and industry. Its products include androstenedione, lovastatin, and simvastatin, which are used for anti-cholesterol and steroid intermediate applications. The company also develops various produ… Read more
Krebs Biochemicals and Industries Limited - Asset Resilience Ratio
Krebs Biochemicals and Industries Limited (KREBSBIO) has an Asset Resilience Ratio of 0.02% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2006–2025)
This chart shows how Krebs Biochemicals and Industries Limited's Asset Resilience Ratio has changed over time. Compare with other companies' asset resilience ratios.
Liquid Assets Composition Over Time
This chart breaks down Krebs Biochemicals and Industries Limited's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₹0.00 | 0% |
| Short-term Investments | ₹307.00K | 0.02% |
| Total Liquid Assets | ₹307.00K | 0.02% |
Asset Resilience Insights
- Limited Liquidity: Krebs Biochemicals and Industries Limited maintains only 0.02% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Krebs Biochemicals and Industries Limited Industry Peers by Asset Resilience Ratio
Compare Krebs Biochemicals and Industries Limited's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Biostar Pharmaceuticals Inc
PINK:BSPM |
Drug Manufacturers - Specialty & Generic | 0.00% |
|
High Sierra Technologies Inc
PINK:HSTI |
Drug Manufacturers - Specialty & Generic | 0.01% |
|
Dongwha Pharm.Co.Ltd
KO:000020 |
Drug Manufacturers - Specialty & Generic | 1.92% |
|
Shenzhen Neptunus Bioengineering Co Ltd
SHE:000078 |
Drug Manufacturers - Specialty & Generic | 0.46% |
|
Yuhan Corp.
KO:000100 |
Drug Manufacturers - Specialty & Generic | 0.99% |
|
Anhui Fengyuan Pharmaceutical Co Ltd
SHE:000153 |
Drug Manufacturers - Specialty & Generic | 1.81% |
|
Shan Dong Dong-E E-Jiao Co Ltd
SHE:000423 |
Drug Manufacturers - Specialty & Generic | 20.44% |
|
Kotra Industries Bhd
KLSE:0002 |
Drug Manufacturers - Specialty & Generic | 9.82% |
Annual Asset Resilience Ratio for Krebs Biochemicals and Industries Limited (2006–2025)
The table below shows the annual Asset Resilience Ratio data for Krebs Biochemicals and Industries Limited.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-03-31 | 0.12% | ₹1.96 Million | ₹1.69 Billion | -1.57pp |
| 2024-03-31 | 1.69% | ₹30.13 Million | ₹1.78 Billion | +1.53pp |
| 2023-03-31 | 0.16% | ₹2.86 Million | ₹1.75 Billion | +0.05pp |
| 2022-03-31 | 0.11% | ₹2.11 Million | ₹1.90 Billion | -0.12pp |
| 2021-03-31 | 0.23% | ₹3.67 Million | ₹1.59 Billion | +0.14pp |
| 2020-03-31 | 0.09% | ₹1.18 Million | ₹1.34 Billion | -10.34pp |
| 2019-03-31 | 10.43% | ₹148.43 Million | ₹1.42 Billion | +10.08pp |
| 2018-03-31 | 0.35% | ₹4.37 Million | ₹1.26 Billion | -4.69pp |
| 2017-03-31 | 5.03% | ₹61.45 Million | ₹1.22 Billion | +2.75pp |
| 2015-03-31 | 2.29% | ₹27.32 Million | ₹1.19 Billion | +2.25pp |
| 2008-03-31 | 0.04% | ₹719.47K | ₹2.00 Billion | -0.13pp |
| 2007-03-31 | 0.17% | ₹3.56 Million | ₹2.12 Billion | -0.17pp |
| 2006-03-31 | 0.34% | ₹7.84 Million | ₹2.33 Billion | -- |